Adicet Bio Inc (ACET)

$0.89 +0.03 (3.34%)
Market Cap 74.10M
Revenue (ttm) 0.00
Net Income (ttm) -117.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 955,400
Avg Vol 1,445,512
Day's Range N/A - N/A
Shares Out 83.25M
Stochastic %K 17%
Beta 1.62
Analysts Strong Sell
Price Target $6.33

Company Profile

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmun...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 503 9095
Address:
131 Dartmouth Street, 3rd Floor, Boston, United States
Stocklord6
Stocklord6 Oct. 24 at 10:47 PM
$ACET 500 calls for $2.50 by 2026.
0 · Reply
ralf2906
ralf2906 Oct. 23 at 8:18 PM
$ACET every thing I touch turns to shift... unbelievable
2 · Reply
Zgod
Zgod Oct. 23 at 7:10 PM
$ACET a little pullback but looks to be stabilized now. Not too concerned about this one, very bullish long term!
0 · Reply
GladysFoster
GladysFoster Oct. 23 at 4:59 AM
$ACET the least deepest cut yesterday. Hopefully a good sign
0 · Reply
Gator5326
Gator5326 Oct. 22 at 8:18 PM
$ACET Possibilities are endless 😎
0 · Reply
GladysFoster
GladysFoster Oct. 22 at 9:44 AM
$ACET Not a great deal going on here
0 · Reply
NEWBIGTECH
NEWBIGTECH Oct. 20 at 5:59 PM
$ACET
0 · Reply
WARBUD
WARBUD Oct. 20 at 12:27 PM
$ACET
0 · Reply
GladysFoster
GladysFoster Oct. 20 at 10:57 AM
$ACET any more upcoming catalyst worth mentioning?
0 · Reply
GladysFoster
GladysFoster Oct. 20 at 10:55 AM
$ACET new here. I see ADI‑001 (autoimmune / B-cell) and ADI‑270 (solid tumour) have Fast Track. What sort of time span are they expecting a decision? Thanks in advance
0 · Reply
Latest News on ACET
Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)

Oct 16, 2025, 7:00 AM EDT - 9 days ago

Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)

Adicet Bio, Inc. - Special Call

Oct 7, 2025, 12:35 PM EDT - 18 days ago

Adicet Bio, Inc. - Special Call

Adicet Bio's Lupus Trial Delivers 100% Response, Setting Stage For Phase 2

Oct 7, 2025, 11:05 AM EDT - 18 days ago

Adicet Bio's Lupus Trial Delivers 100% Response, Setting Stage For Phase 2

Adicet Bio, Inc. Announces $80 Million Registered Direct Offering

Oct 7, 2025, 7:01 AM EDT - 18 days ago

Adicet Bio, Inc. Announces $80 Million Registered Direct Offering

Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

Oct 7, 2025, 6:45 AM EDT - 18 days ago

Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Sep 30, 2025, 4:27 PM EDT - 25 days ago

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 7:00 AM EDT - 7 weeks ago

Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Aug 29, 2025, 4:48 PM EDT - 2 months ago

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 7, 2025, 4:01 PM EDT - 2 months ago

Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference

Aug 5, 2025, 7:00 AM EDT - 2 months ago

Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference

Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Jul 24, 2025, 7:00 AM EDT - 3 months ago

Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference

May 21, 2025, 4:00 PM EDT - 5 months ago

Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

May 6, 2025, 4:01 PM EDT - 6 months ago

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference

Apr 30, 2025, 7:00 AM EDT - 6 months ago

Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference

Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

Apr 28, 2025, 4:30 PM EDT - 6 months ago

Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

Adicet Bio Appoints Michael Grissinger to the Board of Directors

Apr 17, 2025, 7:00 AM EDT - 6 months ago

Adicet Bio Appoints Michael Grissinger to the Board of Directors

Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 31, 2025, 5:12 PM EDT - 7 months ago

Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 31, 2025, 7:00 AM EDT - 7 months ago

Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

Mar 6, 2025, 4:01 PM EST - 8 months ago

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

Mar 3, 2025, 7:00 AM EST - 8 months ago

Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)

Feb 27, 2025, 7:00 AM EST - 8 months ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

Feb 5, 2025, 7:10 AM EST - 9 months ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

Jan 29, 2025, 7:00 AM EST - 9 months ago

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones

Jan 8, 2025, 4:10 PM EST - 10 months ago

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones

Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Dec 19, 2024, 7:00 AM EST - 11 months ago

Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

Dec 18, 2024, 7:00 AM EST - 11 months ago

Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Nov 18, 2024, 4:00 PM EST - 1 year ago

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Nov 18, 2024, 7:00 AM EST - 1 year ago

Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

Nov 16, 2024, 9:00 AM EST - 1 year ago

Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 6, 2024, 4:00 PM EST - 1 year ago

Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates

Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024

Nov 5, 2024, 7:00 AM EST - 1 year ago

Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024

Adicet Bio to Participate in Upcoming Investor Conferences

Nov 1, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in Upcoming Investor Conferences

Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Oct 16, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Adicet Bio to Present at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference

Sep 30, 2024, 4:30 PM EDT - 1 year ago

Adicet Bio to Present at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference

Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue

Sep 19, 2024, 7:00 AM EDT - 1 year ago

ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue

Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 27, 2024, 4:00 PM EDT - 1 year ago

Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors

Aug 19, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors

Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates

Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Jul 8, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

Jun 5, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference

May 29, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference

Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates

May 14, 2024, 4:01 PM EDT - 1 year ago

Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates

Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress

May 14, 2024, 10:00 AM EDT - 1 year ago

Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress

Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Apr 22, 2024, 4:30 PM EDT - 1 year ago

Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference

Apr 8, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference

Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Mar 19, 2024, 4:10 PM EDT - 1 year ago

Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Mar 11, 2024, 7:00 AM EDT - 1 year ago

Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Feb 5, 2024, 4:01 PM EST - 1 year ago

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Stocklord6
Stocklord6 Oct. 24 at 10:47 PM
$ACET 500 calls for $2.50 by 2026.
0 · Reply
ralf2906
ralf2906 Oct. 23 at 8:18 PM
$ACET every thing I touch turns to shift... unbelievable
2 · Reply
Zgod
Zgod Oct. 23 at 7:10 PM
$ACET a little pullback but looks to be stabilized now. Not too concerned about this one, very bullish long term!
0 · Reply
GladysFoster
GladysFoster Oct. 23 at 4:59 AM
$ACET the least deepest cut yesterday. Hopefully a good sign
0 · Reply
Gator5326
Gator5326 Oct. 22 at 8:18 PM
$ACET Possibilities are endless 😎
0 · Reply
GladysFoster
GladysFoster Oct. 22 at 9:44 AM
$ACET Not a great deal going on here
0 · Reply
NEWBIGTECH
NEWBIGTECH Oct. 20 at 5:59 PM
$ACET
0 · Reply
WARBUD
WARBUD Oct. 20 at 12:27 PM
$ACET
0 · Reply
GladysFoster
GladysFoster Oct. 20 at 10:57 AM
$ACET any more upcoming catalyst worth mentioning?
0 · Reply
GladysFoster
GladysFoster Oct. 20 at 10:55 AM
$ACET new here. I see ADI‑001 (autoimmune / B-cell) and ADI‑270 (solid tumour) have Fast Track. What sort of time span are they expecting a decision? Thanks in advance
0 · Reply
Haunting_Low
Haunting_Low Oct. 20 at 10:47 AM
$ACET considering the announcement of a huge ATM comparative to current shares, this is holding up well. Especially considering wider market volatility. See what happens this week 🤞
0 · Reply
Stocklord6
Stocklord6 Oct. 20 at 3:44 AM
$ACET back to .70s
0 · Reply
WARBUD
WARBUD Oct. 17 at 8:42 PM
$ACET ... and, another load zone..
1 · Reply
Amb8675309
Amb8675309 Oct. 17 at 3:32 PM
$ACET wondering why it’s down today
1 · Reply
ibaian
ibaian Oct. 17 at 1:53 AM
$ACET will fly soon
0 · Reply
SocioCobb
SocioCobb Oct. 17 at 12:46 AM
$ACET Just getting started, imo. Godspeed bulls!
0 · Reply
WARBUD
WARBUD Oct. 17 at 12:29 AM
$ACET Other than ACET how many greenies in your watch list today? ;)
0 · Reply
KiingDrew
KiingDrew Oct. 16 at 7:11 PM
Would be nice to see $ACET keep riding this momentum
0 · Reply
DaarT5903
DaarT5903 Oct. 16 at 6:21 PM
$ACET $2.5 by January ? What do you guys honestly think
1 · Reply
NEWBIGTECH
NEWBIGTECH Oct. 16 at 6:20 PM
$ACET
0 · Reply
NEWBIGTECH
NEWBIGTECH Oct. 16 at 6:20 PM
$ACET
0 · Reply
NEWBIGTECH
NEWBIGTECH Oct. 16 at 6:20 PM
$ACET
0 · Reply